中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

29 records (took 0.042 seconds)

    Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
    22.
    发明授权
    Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof 有权
    结合淋巴细胞活化基因-3（LAG-3）的抗体的优化及其应用

    公开(公告)号：US09505839B2

    公开(公告)日：2016-11-29

    申请号：US14093867

    申请日：2013-12-02

    Applicant: BRISTOL-MYERS SQUIBB COMPANY

    Inventor： Nils Lonberg ,  Mohan Srinivasan

    IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  C07K16/18 ,  A61K45/06 ,  A61K47/48 ,  A61K39/00

    CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6849 ,  A61K2039/507 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/3061 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

    Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

    Abstract translation: 本发明提供了与之前描述的抗LAG-3抗体（例如抗体25F7）（US 2011/0150892 A1）相比特异性结合LAG-3的分离的单克隆抗体，并具有优化的功能特性。 这些性质包括减少的脱酰胺位点，同时保持与人LAG-3的高亲和力结合，以及物理（即热和化学）稳定性。 还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和用于表达本发明的抗体的方法，以及免疫偶联物，双特异性分子和包含该抗体的药物组合物。 本发明还提供了用于检测LAG-3的方法，以及使用本发明的抗LAG-3抗体治疗刺激性免疫应答的方法。 还提供了其中抗体与至少一种另外的免疫刺激性抗体共同施用的联合治疗。

    Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
    25.
    发明授权
    Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof 有权

    公开(公告)号：US11345752B2

    公开(公告)日：2022-05-31

    申请号：US16288245

    申请日：2019-02-28

    Applicant: Bristol-Myers Squibb Company

    Inventor： Nils Lonberg ,  Mohan Srinivasan

    IPC: C07H21/00 ,  C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  A61K45/06 ,  A61K47/68 ,  C07K16/30 ,  A61K39/00

    Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

Patent Agency Ranking